Former "The Hills" star Spencer Pratt files to run for LA mayor, accusing current leaders of mismanagement and calling the ...

The biotech is developing drugs that target the biology of aging to treat obesity, cardiovascular disease, and more ...

The pharmaceutical sector is famously volatile, usually driven by the binary outcomes of clinical trials. A drug either works ...

Without greed, we wouldn’t have many of the benefits we enjoy today, such as cars, heated homes and computers, argue our ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $496.45, a high estimate of $564.00, and a low estimate of $414.00. Witnessing a positive shift, the ...

G&A Expense -- $1.9 million, down from $2.3 million mainly due to lower compensation and recruitment spending. Cash on ...

Operating Expenses -- $7 million, up $2 million year over year, with $900,000 tied to R&D investment in the data platform, $200,000 to Corellia’s target discovery, and $800,000 to G&A primarily from ...

By the end of March, the agency could approve multiple “national priority” voucher winners, as well as a gene therapy it ...

As we head into the 2026, let's take a look at biotech licensing deals and M&As that were inked in December 2025.

Vertex Pharmaceuticals (VRTX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Together, these forces position radiopharma as a frontier of medical innovation with ripple effects across healthcare, ...

Outside of pharmaceuticals, behavioral and mental health services are another major contributor to rising employer costs.